Results 111 to 120 of about 910,008 (206)

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach [PDF]

, 2018
Background: TRK fusion cancer results from gene fusions involving NTRK1, NTRK2 or NTRK3. Larotrectinib, the first selective TRK inhibitor, has demonstrated an overall response rate (ORR) of 75% with a favorable safety profile in the first 55 ...
Albert, C. M., Berlin, J. D., Bielack, S. S., Cox, M. C., Cruickshank, S., Doz, F., Drilon, A., Dubois, S. G., Federman, N., Geoerger, B., Hong, D. S., Ku, N. C., Kummar, S., Lassen, U. N., Mascarenhas, L., McDermott, R., Oh, D. Y., Schilder, R. J., Tan, D. S., van Tilburg, C. M.   +19 more
core   +1 more source

LHC Signals from Cascade Decays of Warped Vector Resonances

, 2016
Recently (arXiv:1608.00526), a new framework for warped higher-dimensional compactifications with "bulk" standard model (SM) was proposed: in addition to the UV (Planck scale) and IR (a couple of TeV) branes, there is an intermediate brane, taken to be ...
Agashe, Kaustubh S., Collins, Jack, Du, Peizhi, Hong, Sungwoo, Kim, Doojin, Mishra, Rashmish K.   +5 more
core   +1 more source

Measurement of the tt¯ production cross section in pp¯ collisions at √s = 1.96 TeV using events with large missing transverse energy and jets [PDF]

, 2011
Aaltonen, T., Álvarez González, B., Amerio, S., Amidei, D., Anastassov, A., Annovi, A., Antos, J., Apollinari, G., Appel, J.A., Apresyan, A., Arisawa, T., Artikov, A., Asaadi, J., Ashmanskas, W., Auerbach, B., Aurisano, A., Azfar, F., Badgett, W ...
Aaltonen, T., Amerio, Silvia, CDF Collaboration, Cuevas Maestro, Francisco Javier, Álvarez González, Bárbara   +4 more
core   +1 more source

A Giant Thoracic ALK‐Rearranged Mesenchymal Neoplasm in a Child

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background Mesenchymal neoplasms characterized by ALK fusions mainly include inflammatory myofibroblastic tumors (IMTs) and epithelioid fibrous histiocytomas (EFHs). More recently, ALK‐rearranged mesenchymal tumors that are not IMTs or EFHs, characterized by S100 and CD34 coexpression, have been reported in a few small series and isolated case
Sheng Gao, Junhua Wu, Jun Fan, Xiaona Chang, Bo Huang, Danju Luo, Jun He, Heshui Shi, Xiaochuan Dong, Xiu Nie   +9 more
wiley   +1 more source

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas : expert recommendations from the World Sarcoma Network [PDF]

, 2020
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new personalized therapies for a ...
Antonescu, C. R., Bjerkehagen, B., Blay, J-Y, Bovee, J. V. M. G., Boye, K., Chacon, M., Dei Tos, A. P., Demetri, G. D., Desai, J., Fletcher, J. A., Gelderblom, H., George, S., Gronchi, A., Haas, R. L., Hall, K. Sundby, Hindi, N., Hohenberger, P., Joensuu, H., Jones, R. L., Judson, Ian, Kang, Y-K, Kawai, A., Lazar, A. J., Le Cesne, A., Maestro, R., Maki, Rg, Martin, J., Naito, Y., Patel, S., Penault-Llorca, F., Raut, C. Premanand, Rutkowski, P., Safwat, A., Sbaraglia, M., Schaefer, I-M, Schoffski, P., Serrano, C., Shen, L., Stacchiotti, S., Tap, W. D., Thomas, D. M., Trent, J., Valverde, C., van der Graaf, W. T. A., von Mehren, M., Wagner, A., Wardelmann, E., Zalcberg, J.   +47 more
core   +5 more sources

Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG‐TOP2 Study

Cancer Science, Volume 117, Issue 2, Page 522-535, February 2026.
In the JCCG‐TOP2 nationwide pediatric cancer genomic profiling study, 204 patients' tumors and peripheral blood from 50 institutions across Japan were successfully analyzed using a dual DNA/RNA panel. A total of 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%),
Kayoko Tao, Takako Yoshioka, Miho Kato, Kazuyuki Komatsu, Shinichi Tsujimoto, Kenichi Sakamoto, Kazuki Tanimura, Minako Sugiyama, Masahiro Sekiguchi, Yoshiko Nakano, Yoshihiro Otani, Yasushi Yatabe, Akihiko Yoshida, Hajime Okita, Junko Hirato, Kenichi Kohashi, Yukichi Tanaka, Shinji Kohsaka, Takashi Kubo, Kuniko Sunami, Makoto Hirata, Shuichi Tsutsumi, Hiroyuki Aburatani, Katsuyoshi Koh, Masahiro Hirayama, Shuhei Karakawa, Yukayo Terashita, Hiroyuki Fujisaki, Takeshi Yagi, Akihiro Yoneda, Shinji Mochizuki, Hiroyuki Shichino, Tatsuya Suzuki, Tetsuya Takimoto, Koichi Ichimura, Chitose Ogawa, Kimikazu Matsumoto, Hitoshi Ichikawa, Motohiro Kato   +38 more
wiley   +1 more source

NTRK gene aberrations in triple‐negative breast cancer: detection challenges using IHC, FISH, RT‐PCR, and NGS

The Journal of Pathology: Clinical Research, 2023
Triple‐negative breast cancer (TNBC) is usually an aggressive disease with a poor prognosis and limited treatment options. The neurotrophic tyrosine receptor kinase (NTRK) gene fusions are cancer type‐agnostic emerging biomarkers approved by the Food and
Federica Zito Marino, Simona Buono, Marco Montella, Rosa Giannatiempo, Francesco Messina, Giovanni Casaretta, Grazia Arpino, Giulia Vita, Francesco Fiorentino, Luigi Insabato, Alessandro Sgambato, Michele Orditura, Renato Franco, Marina Accardo   +13 more
doaj   +1 more source

WHO classification of skin tumours: key updates in the fifth edition

Histopathology, Volume 88, Issue 3, Page 555-568, February 2026.
This review article summarizes the key updates in the 5th edition of the WHO Classification of Skin Tumours. It provides an overview of the major changes and new entities specific to the skin section, covering areas such as epidermal, melanocytic, mesenchymal and other tumours. The 5th edition of the World Health Organization Classification of Tumours (
Gabrielle Goldman‐Lévy, Raymond Barnhill, Boris C. Bastian, Werner Kempf, David Elder, Pedram Gerami, Wayne Grayson, Dmitry Kazakov, Daniela Massi, Jane Messina, Arnaud de la Fouchardière, Alexander J. Lazar, Thomas Brenn, Brian Rous, Andrew Field, Anthony Gill, Jennelle C. Hodge, Joseph D Khoury, Katia Leite, Shahin Sayed, Puay Hoon Tan, Rosalie Elenitsas, Eduardo Calonje, Lyn M. Duncan, Liang Zhiyong, Holger Moch, Rajendra Singh, Harshima Wijesinghe, Ian Cree, Dilani Lokuhetty   +29 more
wiley   +1 more source

Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets

Cancer Medicine
Background Receptor tyrosine kinase (RTK) inhibitors have been approved for the treatment of NTRK fusion (NTRK+) and RET fusion (RET+) positive solid tumors in a tumor‐agnostic manner. However, the objective response rate was the lowest among entrectinib‐
Zhaohui Liao Arter, Alexandria T. M. Lee, Misako Nagasaka, Sai‐Hong Ignatius Ou   +3 more
doaj   +1 more source

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas

American Journal of Hematology, Volume 101, Issue 1, Page 110-128, January 2026.
ABSTRACT The tumor necrosis factor (TNF)‐receptor superfamily 8 receptor CD30 molecule is expressed in all tumor cells of Hodgkin lymphoma and anaplastic large cell lymphoma but is only weakly expressed in a small subset of large lymphoid cells in normal peripheral lymphoid tissues.
Harald Stein, Brunangelo Falini
wiley   +1 more source